These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9096181)

  • 41. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antibiotic sensitivity and pyocin dependence of clinical strains of Ps. aeruginosa].
    Savitskaia KI; Levina EN
    Antibiotiki; 1977 Dec; 22(12):1117-21. PubMed ID: 413475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Pseudomonas aeruginosa isolated in major hospitals in Nagano prefecture].
    Hachiya T; Kubo K; Yanagisawa H
    Jpn J Antibiot; 2004 Apr; 57(2):157-71. PubMed ID: 15219055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pyocin typing of Pseudomonas aeruginosa strains isolated from various sources].
    Kantarci G
    Mikrobiyol Bul; 1992 Jan; 26(1):17-25. PubMed ID: 1574018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa.
    Penterman J; Singh PK; Walker GC
    J Bacteriol; 2014 Sep; 196(18):3351-9. PubMed ID: 25022851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The enhancing effect of EDTA on the antibacterial activity of nalidixic acid against Pseudomonas aeruginosa.
    Nezval J; Halacka K
    Experientia; 1967 Dec; 23(12):1043-4. PubMed ID: 4965667
    [No Abstract]   [Full Text] [Related]  

  • 48. [Phenotypic relations with regard to pyocin sensitivity, of 191 strains of Pseudomonas aeruginosa isolated in a hospital environment].
    Santini G; Targa S; Basaglia M; Marchetti G; Crovatto M
    Boll Ist Sieroter Milan; 1983 Jul; 62(3):242-6. PubMed ID: 6416270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt.
    Gad GF; el-Domany RA; Ashour HM
    J Urol; 2008 Jul; 180(1):176-81. PubMed ID: 18499192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa.
    Hostacká A
    Pharmazie; 1997 Jul; 52(7):544-6. PubMed ID: 9266592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isolation, purification and characterization of a pyocin.
    Faydi YR; Nabbut NH
    Ann Microbiol (Paris); 1978 Apr; 129(3):313-22. PubMed ID: 96719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship of resistance phenotype to the R-pyocin susceptibility pattern in clinical isolates of Pseudomonas aeruginosa.
    Petrocheilou-Malliara K; Koukoubanis N; Legakis N
    Chemioterapia; 1987 Jun; 6(2 Suppl):199. PubMed ID: 3151341
    [No Abstract]   [Full Text] [Related]  

  • 53. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotyping and pyocin typing of Pseudomonas aeruginosa from clinical specimens.
    Kurup VP; Sheth NK
    Am J Clin Pathol; 1976 Apr; 65(4):557-63. PubMed ID: 817593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic stress induces a large amount of outer membrane protein in Pseudomonas aeruginosa.
    Nakajima A; Hoshikawa M; Nakae T
    FEMS Microbiol Lett; 1998 Aug; 165(2):261-5. PubMed ID: 9742697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoroquinolone supersusceptibility mediated by outer membrane protein OprH overexpression in Pseudomonas aeruginosa: evidence for involvement of a nonporin pathway.
    Young M; Hancock RE
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2365-9. PubMed ID: 1336943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Structure and Functional Analysis of Pyocin S8 from Pseudomonas aeruginosa Reveals the Essential Requirement of a Glutamate Residue in the H-N-H Motif for DNase Activity.
    Turano H; Gomes F; Domingos RM; Degenhardt MFS; Oliveira CLP; Garratt RC; Lincopan N; Netto LES
    J Bacteriol; 2020 Oct; 202(21):. PubMed ID: 32817098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.